STOCK TITAN

Mirum Pharmaceuticals Inc - MIRM STOCK NEWS

Welcome to our dedicated news page for Mirum Pharmaceuticals (Ticker: MIRM), a resource for investors and traders seeking the latest updates and insights on Mirum Pharmaceuticals.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Mirum Pharmaceuticals's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Mirum Pharmaceuticals's position in the market.

Rhea-AI Summary
Mirum Pharmaceuticals, Inc. reported third quarter 2023 total revenue of $47.7 million. They completed the acquisition of CHENODAL and CHOLBAM. They also announced positive Phase 3 RESTORE study results for CHENODAL. The company expects to file a New Drug Application for CHENODAL in the first half of 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.67%
Tags
-
Rhea-AI Summary
Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) will present data from its LIVMARLI and volixibat programs at The Liver Meeting®, showcasing long-term maintenance of response in patients with progressive familial intrahepatic cholestasis (PFIC) and improvements in pruritus and quality of life. The presentations will take place on November 13, 2023, in Boston, Massachusetts.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.41%
Tags
conferences
-
Rhea-AI Summary
Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) will report Q3 2023 financial results on November 2nd, 2023. Conference call to discuss results and recent corporate progress will be held. Dial-in and webcast details provided.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.45%
Tags
Rhea-AI Summary
Mirum Pharmaceuticals announces FDA's extension of review for LIVMARLI oral solution
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.29%
Tags
none
-
Rhea-AI Summary
Mirum Pharmaceuticals grants inducement awards to new employees
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.79%
Tags
none
-
Rhea-AI Summary
Mirum Pharmaceuticals presents analyses demonstrating benefits of LIVMARLI in patients with ALGS and PFIC
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
Rhea-AI Summary
Mirum Pharmaceuticals announces positive data from Phase 3 RESTORE study of Chenodal in CTX patients, meeting primary endpoint with a 20-fold reduction in urine bile alcohols (p<0.0001). Plasma cholestanol endpoint also met (p=0.0083). NDA to be filed with FDA in H1 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.28%
Tags
-
Rhea-AI Summary
Mirum Pharmaceuticals announces data presentation at NASPGHAN annual meeting
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.87%
Tags
none
-
Rhea-AI Summary
Mirum Pharmaceuticals to participate in fireside chat at Cantor Global Healthcare Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.7%
Tags
conferences
Rhea-AI Summary
Mirum Pharmaceuticals appoints Eric Bjerkholt as CFO, bringing extensive business leadership experience from the biopharmaceutical industry. Bjerkholt's appointment is seen as important for Mirum's growth and global scale. He is granted 110,000 shares of common stock and 55,000 restricted stock units. Bjerkholt's appointment and stock grants indicate positive prospects for Mirum's future.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.35%
Tags
management
Mirum Pharmaceuticals Inc

Nasdaq:MIRM

MIRM Rankings

MIRM Stock Data

1.16B
35.19M
2.25%
112.23%
17.36%
Research and Development in Biotechnology
Professional, Scientific, and Technical Services
Link
United States
Foster City

About MIRM

mirum pharmaceuticals, inc., a biopharmaceutical company, focuses on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases. its lead product candidate is maralixibat, an investigational oral drug that is in phase 3 clinical trial for the treatment of progressive familial intrahepatic cholestasis disease, as well as for the treatment of alagille syndrome and biliary atresia disease. the company is also develops volixibat drug for treatment of intrahepatic cholestasis of pregnancy and primary sclerosing cholangitis. mirum pharmaceuticals, inc. was founded in 2018 and is headquartered in foster city, california.